As advocates for equitable care, we must ensure that every New Yorker diagnosed with glioblastoma (GBM) can access the life-extending benefits of Optune, regardless of income. Optune (Tumor Treating Fields) is FDA-approved and NCCN-recommended for GBM, but without a Medicaid mandate, low-income patients in New York remain unable to receive this proven therapy. In December 2024, the NYS Department of Health’s review committee voted to approve Optune coverage under Medicaid, yet implementation is stalled by budget concerns. S 6736A (for your senator) and A 6935A (for your assemblymember) will require Medicaid FFS to cover Optune effective April 1, 2026.
We need you to log on, complete the official online contact forms for your state senator and assemblymember, and ask them to vote “Yes” on S 6736A / A 6935A before the session adjourns on June 12, 2025. This is the fastest and most direct way to let your legislators know that New Yorkers demand equitable access to Optune. If you are able, please also share this call to action with friends and family across New York so they can submit their own letters—every message counts.
Support S 6736A – Medicaid Coverage for Optune (TTFields)
Dear Senator [Last Name],
I am a constituent living at [Your Full Address]. I respectfully ask you to vote “Yes” on S 6736A, which would require Medicaid Fee-for-Service to cover Optune (Tumor Treating Fields) for glioblastoma starting April 1, 2026. Optune is FDA-approved and NCCN-recommended, yet patients on Medicaid are currently denied access. Requiring coverage will ensure that low-income New Yorkers can benefit from this life-extending treatment. Please support S 6736A before the June 12, 2025 adjournment.
Thank you for your consideration.
Sincerely,
[Your Name]
[City, NY ZIP]
Support A 6935A – Medicaid Coverage for Optune (TTFields)
Dear Assemblymember [Last Name],
I am a constituent living at [Your Full Address]. I respectfully ask you to vote “Yes” on A 6935A, which would require Medicaid Fee-for-Service to cover Optune (Tumor Treating Fields) for glioblastoma starting April 1, 2026. Optune is FDA-approved and NCCN-recommended, yet GBM patients on Medicaid are currently denied access. Requiring coverage will ensure that low-income New Yorkers can benefit from this life-extending treatment. Please support A 6935A before the June 12, 2025 adjournment.
Thank you for your consideration.
Sincerely,
[Your Name]
[City, NY ZIP]
Thank you for standing up for New Yorkers with GBM. By completing these online forms today—and asking others to do the same—you help ensure that Medicaid covers Optune beginning April 1, 2026, giving patients a fighting chance.